XML 134 R111.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Sales	$ 40,122	$ 39,807	$ 39,498
Proceeds from sale of intangible assets	85	170
Operating Segments
Segment Reporting Information [Line Items]
Sales	39,662	39,013	38,449
Operating Segments | Pharmaceutical segment
Segment Reporting Information [Line Items]
Sales	35,390	35,151	34,782
Operating Segments | Pharmaceutical segment | Zetia
Segment Reporting Information [Line Items]
Sales	1,344	2,560	2,526
Operating Segments | Pharmaceutical segment | Vytorin
Segment Reporting Information [Line Items]
Sales	751	1,141	1,251
Operating Segments | Pharmaceutical segment | Atozet
Segment Reporting Information [Line Items]
Sales	225	146	36
Operating Segments | Pharmaceutical segment | Adempas
Segment Reporting Information [Line Items]
Sales	300	169	30
Operating Segments | Pharmaceutical segment | Januvia
Segment Reporting Information [Line Items]
Sales	3,737	3,908	3,863
Operating Segments | Pharmaceutical segment | Janumet
Segment Reporting Information [Line Items]
Sales	2,158	2,201	2,151
Operating Segments | Pharmaceutical segment | NuvaRing
Segment Reporting Information [Line Items]
Sales	761	777	732
Operating Segments | Pharmaceutical segment | Implanon/Nexplanon
Segment Reporting Information [Line Items]
Sales	686	606	588
Operating Segments | Pharmaceutical segment | Follistim AQ
Segment Reporting Information [Line Items]
Sales	298	355	383
Operating Segments | Pharmaceutical segment | Zepatier
Segment Reporting Information [Line Items]
Sales	1,660	555	0
Operating Segments | Pharmaceutical segment | Isentress/Isentress HD
Segment Reporting Information [Line Items]
Sales	1,204	1,387	1,511
Operating Segments | Pharmaceutical segment | Bridion
Segment Reporting Information [Line Items]
Sales	704	482	353
Operating Segments | Pharmaceutical segment | Noxafil
Segment Reporting Information [Line Items]
Sales	636	595	487
Operating Segments | Pharmaceutical segment | Invanz
Segment Reporting Information [Line Items]
Sales	602	561	569
Operating Segments | Pharmaceutical segment | Cancidas
Segment Reporting Information [Line Items]
Sales	422	558	573
Operating Segments | Pharmaceutical segment | Cubicin
Segment Reporting Information [Line Items]
Sales	382	1,087	1,127
Operating Segments | Pharmaceutical segment | Primaxin
Segment Reporting Information [Line Items]
Sales	280	297	313
Operating Segments | Pharmaceutical segment | Remicade
Segment Reporting Information [Line Items]
Sales	837	1,268	1,794
Operating Segments | Pharmaceutical segment | Simponi
Segment Reporting Information [Line Items]
Sales	819	766	690
Operating Segments | Pharmaceutical segment | Keytruda
Segment Reporting Information [Line Items]
Sales	3,809	1,402	566
Operating Segments | Pharmaceutical segment | Emend
Segment Reporting Information [Line Items]
Sales	556	549	535
Operating Segments | Pharmaceutical segment | Temodar
Segment Reporting Information [Line Items]
Sales	271	283	312
Operating Segments | Pharmaceutical segment | Singulair
Segment Reporting Information [Line Items]
Sales	732	915	931
Operating Segments | Pharmaceutical segment | Nasonex
Segment Reporting Information [Line Items]
Sales	387	537	858
Operating Segments | Pharmaceutical segment | Dulera
Segment Reporting Information [Line Items]
Sales	287	436	536
Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar
Segment Reporting Information [Line Items]
Sales	484	511	667
Operating Segments | Pharmaceutical segment | Arcoxia
Segment Reporting Information [Line Items]
Sales	363	450	471
Operating Segments | Pharmaceutical segment | Fosamax
Segment Reporting Information [Line Items]
Sales	241	284	359
Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	2,308	2,173	1,908
Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	1,676	1,640	1,505
Operating Segments | Pharmaceutical segment | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	821	641	542
Operating Segments | Pharmaceutical segment | RotaTeq
Segment Reporting Information [Line Items]
Sales	686	652	610
Operating Segments | Pharmaceutical segment | Zostavax
Segment Reporting Information [Line Items]
Sales	668	685	749
Operating Segments | Pharmaceutical segment | Other pharmaceutical
Segment Reporting Information [Line Items]
Sales	4,295	4,574	5,256
Operating Segments | Other segments
Segment Reporting Information [Line Items]
Sales	4,272	3,862	3,667
Other
Segment Reporting Information [Line Items]
Sales	460	794	1,049
United States
Segment Reporting Information [Line Items]
Sales	17,424	18,478	17,519
United States | Operating Segments
Segment Reporting Information [Line Items]
Sales	17,340	18,447	17,451
United States | Operating Segments | Pharmaceutical segment
Segment Reporting Information [Line Items]
Sales	15,854	17,073	16,238
United States | Operating Segments | Pharmaceutical segment | Zetia
Segment Reporting Information [Line Items]
Sales	352	1,588	1,612
United States | Operating Segments | Pharmaceutical segment | Vytorin
Segment Reporting Information [Line Items]
Sales	124	473	479
United States | Operating Segments | Pharmaceutical segment | Atozet
Segment Reporting Information [Line Items]
Sales	0	1	2
United States | Operating Segments | Pharmaceutical segment | Adempas
Segment Reporting Information [Line Items]
Sales	0	0	0
United States | Operating Segments | Pharmaceutical segment | Januvia
Segment Reporting Information [Line Items]
Sales	2,153	2,286	2,263
United States | Operating Segments | Pharmaceutical segment | Janumet
Segment Reporting Information [Line Items]
Sales	863	984	976
United States | Operating Segments | Pharmaceutical segment | NuvaRing
Segment Reporting Information [Line Items]
Sales	564	576	515
United States | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon
Segment Reporting Information [Line Items]
Sales	496	420	367
United States | Operating Segments | Pharmaceutical segment | Follistim AQ
Segment Reporting Information [Line Items]
Sales	123	157	160
United States | Operating Segments | Pharmaceutical segment | Zepatier
Segment Reporting Information [Line Items]
Sales	771	488	0
United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD
Segment Reporting Information [Line Items]
Sales	565	721	797
United States | Operating Segments | Pharmaceutical segment | Bridion
Segment Reporting Information [Line Items]
Sales	239	77	0
United States | Operating Segments | Pharmaceutical segment | Noxafil
Segment Reporting Information [Line Items]
Sales	309	284	212
United States | Operating Segments | Pharmaceutical segment | Invanz
Segment Reporting Information [Line Items]
Sales	361	329	322
United States | Operating Segments | Pharmaceutical segment | Cancidas
Segment Reporting Information [Line Items]
Sales	20	25	24
United States | Operating Segments | Pharmaceutical segment | Cubicin
Segment Reporting Information [Line Items]
Sales	189	906	1,030
United States | Operating Segments | Pharmaceutical segment | Primaxin
Segment Reporting Information [Line Items]
Sales	10	4	8
United States | Operating Segments | Pharmaceutical segment | Remicade
Segment Reporting Information [Line Items]
Sales	0	0	0
United States | Operating Segments | Pharmaceutical segment | Simponi
Segment Reporting Information [Line Items]
Sales	0	0	0
United States | Operating Segments | Pharmaceutical segment | Keytruda
Segment Reporting Information [Line Items]
Sales	2,309	792	393
United States | Operating Segments | Pharmaceutical segment | Emend
Segment Reporting Information [Line Items]
Sales	342	356	326
United States | Operating Segments | Pharmaceutical segment | Temodar
Segment Reporting Information [Line Items]
Sales	16	15	7
United States | Operating Segments | Pharmaceutical segment | Singulair
Segment Reporting Information [Line Items]
Sales	40	40	39
United States | Operating Segments | Pharmaceutical segment | Nasonex
Segment Reporting Information [Line Items]
Sales	54	184	449
United States | Operating Segments | Pharmaceutical segment | Dulera
Segment Reporting Information [Line Items]
Sales	261	412	515
United States | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar
Segment Reporting Information [Line Items]
Sales	18	16	30
United States | Operating Segments | Pharmaceutical segment | Arcoxia
Segment Reporting Information [Line Items]
Sales	0	0	0
United States | Operating Segments | Pharmaceutical segment | Fosamax
Segment Reporting Information [Line Items]
Sales	6	5	12
United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	1,565	1,780	1,520
United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	1,374	1,362	1,290
United States | Operating Segments | Pharmaceutical segment | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	581	447	378
United States | Operating Segments | Pharmaceutical segment | RotaTeq
Segment Reporting Information [Line Items]
Sales	481	482	447
United States | Operating Segments | Pharmaceutical segment | Zostavax
Segment Reporting Information [Line Items]
Sales	422	518	592
United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical
Segment Reporting Information [Line Items]
Sales	1,246	1,345	1,473
United States | Operating Segments | Other segments
Segment Reporting Information [Line Items]
Sales	1,486	1,374	1,213
United States | Other
Segment Reporting Information [Line Items]
Sales	84	31	68
Int’l
Segment Reporting Information [Line Items]
Sales	22,698	21,329	21,979
Int’l | Operating Segments
Segment Reporting Information [Line Items]
Sales	22,321	20,566	20,998
Int’l | Operating Segments | Pharmaceutical segment
Segment Reporting Information [Line Items]
Sales	19,536	18,077	18,544
Int’l | Operating Segments | Pharmaceutical segment | Zetia
Segment Reporting Information [Line Items]
Sales	992	972	914
Int’l | Operating Segments | Pharmaceutical segment | Vytorin
Segment Reporting Information [Line Items]
Sales	627	668	771
Int’l | Operating Segments | Pharmaceutical segment | Atozet
Segment Reporting Information [Line Items]
Sales	225	146	34
Int’l | Operating Segments | Pharmaceutical segment | Adempas
Segment Reporting Information [Line Items]
Sales	300	169	30
Int’l | Operating Segments | Pharmaceutical segment | Januvia
Segment Reporting Information [Line Items]
Sales	1,584	1,622	1,601
Int’l | Operating Segments | Pharmaceutical segment | Janumet
Segment Reporting Information [Line Items]
Sales	1,296	1,217	1,175
Int’l | Operating Segments | Pharmaceutical segment | NuvaRing
Segment Reporting Information [Line Items]
Sales	197	202	216
Int’l | Operating Segments | Pharmaceutical segment | Implanon/Nexplanon
Segment Reporting Information [Line Items]
Sales	191	186	221
Int’l | Operating Segments | Pharmaceutical segment | Follistim AQ
Segment Reporting Information [Line Items]
Sales	174	197	223
Int’l | Operating Segments | Pharmaceutical segment | Zepatier
Segment Reporting Information [Line Items]
Sales	888	67	0
Int’l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD
Segment Reporting Information [Line Items]
Sales	639	666	714
Int’l | Operating Segments | Pharmaceutical segment | Bridion
Segment Reporting Information [Line Items]
Sales	465	405	353
Int’l | Operating Segments | Pharmaceutical segment | Noxafil
Segment Reporting Information [Line Items]
Sales	327	312	275
Int’l | Operating Segments | Pharmaceutical segment | Invanz
Segment Reporting Information [Line Items]
Sales	241	233	247
Int’l | Operating Segments | Pharmaceutical segment | Cancidas
Segment Reporting Information [Line Items]
Sales	402	533	548
Int’l | Operating Segments | Pharmaceutical segment | Cubicin
Segment Reporting Information [Line Items]
Sales	193	181	97
Int’l | Operating Segments | Pharmaceutical segment | Primaxin
Segment Reporting Information [Line Items]
Sales	270	293	305
Int’l | Operating Segments | Pharmaceutical segment | Remicade
Segment Reporting Information [Line Items]
Sales	837	1,268	1,794
Int’l | Operating Segments | Pharmaceutical segment | Simponi
Segment Reporting Information [Line Items]
Sales	819	766	690
Int’l | Operating Segments | Pharmaceutical segment | Keytruda
Segment Reporting Information [Line Items]
Sales	1,500	610	173
Int’l | Operating Segments | Pharmaceutical segment | Emend
Segment Reporting Information [Line Items]
Sales	213	193	209
Int’l | Operating Segments | Pharmaceutical segment | Temodar
Segment Reporting Information [Line Items]
Sales	256	268	306
Int’l | Operating Segments | Pharmaceutical segment | Singulair
Segment Reporting Information [Line Items]
Sales	692	874	892
Int’l | Operating Segments | Pharmaceutical segment | Nasonex
Segment Reporting Information [Line Items]
Sales	333	352	409
Int’l | Operating Segments | Pharmaceutical segment | Dulera
Segment Reporting Information [Line Items]
Sales	26	24	21
Int’l | Operating Segments | Pharmaceutical segment | Cozaar/Hyzaar
Segment Reporting Information [Line Items]
Sales	466	494	637
Int’l | Operating Segments | Pharmaceutical segment | Arcoxia
Segment Reporting Information [Line Items]
Sales	363	450	471
Int’l | Operating Segments | Pharmaceutical segment | Fosamax
Segment Reporting Information [Line Items]
Sales	235	279	347
Int’l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	743	393	388
Int’l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	303	279	214
Int’l | Operating Segments | Pharmaceutical segment | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	240	193	164
Int’l | Operating Segments | Pharmaceutical segment | RotaTeq
Segment Reporting Information [Line Items]
Sales	204	169	163
Int’l | Operating Segments | Pharmaceutical segment | Zostavax
Segment Reporting Information [Line Items]
Sales	246	168	157
Int’l | Operating Segments | Pharmaceutical segment | Other pharmaceutical
Segment Reporting Information [Line Items]
Sales	3,049	3,228	3,785
Int’l | Operating Segments | Other segments
Segment Reporting Information [Line Items]
Sales	2,785	2,489	2,454
Int’l | Other
Segment Reporting Information [Line Items]
Sales	$ 377	$ 763	$ 981

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: